Otolaryngological disorders encompass a broad spectrum of conditions that affect the ear, nose, and throat. These conditions often lead to significant discomfort, a reduced quality of life, and the necessity for effective and well-tolerated therapeutic interventions. This article aims to provide an efficacy and safety assessment of VIARINOX^®, a patented technology designed to remove mucus residue from nasal passages in both children and adults, targeting nasal congestion. The study focused on evaluating the antioxidant and anti-inflammatory capacities and the barrier effect of the patented technology. This evaluation involved chemical assays centered on free radical inhibition and assays conducted on reconstructed respiratory epithelium inserts, where damage was induced using LPS. The results obtained indicate that, owing to the presence of sodium hyaluronate, methylsulfonylmethane, and N-acetyl cysteine, this technology could serve as a pharmacological tool for treating otolaryngological disorders and as a preventive measure against the risk of microbial contamination.